Efficacy of maintenance subcutaneous hepatitis B immune globulin (HBIG) post-transplant for prophylaxis against hepatitis B recurrent

Annals of Hepatology

Volumn 9, Issue 2, 2010, Pages 166-171

  Singham, Janakie ^a   Greanya, Erica D ^b   Lau, Kirby ^c   Erb, Siegfried R ^a   Partovi, Nilu ^b   Yoshida, Eric M ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b VANCOUVER GENERAL HOSPITAL   (Canada)

^c British Columbia Transplant Society   (Canada)

Author keywords

HBIG; Hepatitis B; Immune globulin; Liver transplantation; Prophylaxis; Subcutaneus

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; HEPATITIS B ANTIBODY; HYPERHEP B; LAMIVUDINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; UNCLASSIFIED DRUG; ANTIVIRUS AGENT; HEPATITIS B HYPERIMMUNE GLOBULIN; HEPATITIS B VACCINE; IMMUNOGLOBULIN;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ANTIBODY TITER; ARTICLE; CHEMOPROPHYLAXIS; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEPATITIS B; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; PATIENT PREFERENCE; PILOT STUDY; QUESTIONNAIRE; RECURRENT INFECTION; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT RESPONSE; BLOOD; CANADA; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG COMBINATION; INTRAMUSCULAR DRUG ADMINISTRATION; LIVER TRANSPLANTATION; MIDDLE AGED; PATIENT ATTITUDE; PROSPECTIVE STUDY; RECURRENT DISEASE; SUBCUTANEOUS DRUG ADMINISTRATION; TIME; TREATMENT OUTCOME;

ADULT; AGED; ANTIVIRAL AGENTS; BRITISH COLUMBIA; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS B ANTIBODIES; HEPATITIS B VACCINES; HEPATITIS B, CHRONIC; HUMANS; IMMUNOGLOBULINS; INJECTIONS, INTRAMUSCULAR; INJECTIONS, SUBCUTANEOUS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PATIENT PREFERENCE; PILOT PROJECTS; PROSPECTIVE STUDIES; QUESTIONNAIRES; RECURRENCE; TIME FACTORS; TREATMENT OUTCOME;

EID: 77954350427     PISSN: 16652681     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1665-2681(19)31656-4     Document Type: Article

References (27)

1. Olivera-Martinez AM, Gallegos-Orezco JF. Recurrent Viral Liver Disease (Hepatitis B and C) After Liver Transplantation. Archives of Medical Research 2007; 38: 691-701.
2. Eisenbach C, Sahuer P, Mehrabi, et al. Prevention of hepatitis B virus recurrence after liver transplantation. Clinical Transplantation 2006; 20: 111-116.
3. Zuckerman JN. Review: Hepatitis B Immune Globulin for Prevention of Hepatitis B Infection. J Med Virol 2007; 79: 919-921.
4. Yoshida EM, Erb SR, Partovi N, Scudamore CH, Chung SW, et al. Liver transplantation for chronic hepatitis B infection with the use of combination lamivudine and low-dose hepatitis B immune globulin. Liver Transpl Surg 1999; 5: 520-525.
5. Seehofer D, Berg T. Prevention of Hepatitis B Recurrence after Liver Transplantation. Transplantation 2005; 80: S120-S124.
6. Lo CM, Fan ST, Liu CL, et al. Prophylaxis and Treatment of Recurrent Hepatitis B After Liver Transplantation. Transplantation 2003; 75(3): S41-S44.
7. Powell JJ, Apiratpracha W, Partovi N, et al. Subcutaneous administration of hepatitis B immune globulin in combination with lamivudine following orthotopic liver transplantation: effective prophylaxis against recurrence. Clinical Transplantation 2006; 20: 524-525.
8. Partovi N, Guy MW, Ensom MHH, Noble MA, Yoshida EM. A study of the pharmacokinetic profile of low-dose hepatitis B immune globulin in long-term liver transplant recipients for chronic hepatitis B. Am J Transpl 2001; 1: 51-54.
9. Shouval D, Samuel D. Hepatitis B immune globulin to prevent hepatitis B virus graft re-infection following liver transplantation: a concise review. Hepatology 2000; 32: 1189-1195.
10. Vierling JM. Management of hepatitis B infection in liver transplantation. Int J Med Sci 2005; 2: 41-49.
11. Samuel D, Muller R, Alexander G, Fassati L, Ducot B, Ben-hamou JP, et al. Liver transplantation in European pa-tients with the hepatitis B surface antigen. N Engl J Med 1993; 329: 1842-1847.
12. Butt M, Mas A, Prieto M, et al. A randomized study comparing lamivudine monotherapy after a short course of hepatitis B immune globulin (HBIg) and lamivudine with long-term lamivudine plus HBIg in the prevention of hepatitis B virus recurrence after liver transplantation. J Hepatol 2003: 38: 811.
13. Schilling R, Ijaz S, Davidoff M et al. Endocytosis of hepatitis B immune globulin into hepatocytes inhibits the secretion of hepatitis B virus surface antigen and virions. J Virol 2003: 77: 8882.
14. Kim WR, Poterucha JJ, Kremers WK, Ishitani MB, Dickson ER. Outcome of liver transplantation for hepatitis B in the United States. Liver Transpl 2004;10: 968-974.
15. Angus PW, McCaughan GW, Gane EJ, Crawford DH, Harley MH. Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against post-transplantation hepatitis B. Liver Transpl 2000; 6: 429-433.
16. Samuel D, Bismuth A, Mathieu D et al. Passive immunopro-phylaxis after liver transplantation in HBsAgpositive patients. Lancet 1991: 337: 813.
17. Sawyer RG, McGory RW, Gaffey MJ et al. Improved clinical outcomes with liver transplantation for hepatitis Bindu-ced chronic liver failure using passive immunization. Ann Surg 1998: 227: 841.
18. Mq, Cai CJ, Zhao H, Yang Y, Chen GH. Prevention and treatment of hepatitis B virus reinfection after liver transplantation. Zhonghua Wai Ke Za Zhi 2006; 44: 742-744.
19. Han SH, Martin P, Edelstein M, et al. Conversion from intravenous to intramuscular hepatitis B immune globulin in combination with lamivudine is safe and cost-effective in patients receiving long-term prophylaxis to prevent hepatitis B recurrence after liver transplantation. Liver Transpl 2003; 9: 182.
20. Yao FY, Osorio RW, Roberts JP et al. Intramuscular hepatitis B immune globulin combined with lamivudine for prophylaxis against hepatitis B recurrence after liver transplantation. Liver Transpl Surg 1999: 5: 491.
21. Faust D, Rabenau HF, Allwinn R, Caspary WF, Zeuzem S. Cost-effective and safe ambulatory long-term immunoprophylaxis with intramuscular instead of intravenous hepatitis B immunoglobulin to prevent reinfection after orthotopic liver transplantation. Clin Transplant 2003; 17: 254.
22. Angus PW, Patterson SJ, Strasser SI et al. A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxis. Hepatology 2008; 48: 1460-1406.
23. Uri O and Arad E. Skin necrosis after self-administered intramuscular diclofenac. J Plast Reconstr Aesthet Surg 2009; Feb 27. [Epub ahead of print]
24. Luton K, Garcia C, Poletti E, Koester AD, et al. Nicolau Syndrome: three cases and review. Int J Dermatol 2006; 45(11): 1326-1328.
25. Hagenmeyer EG, Shadlich PK, Koster AD, et al. [Quality of life and treatment satisfaction in patients being treated with long-acting insulin analogues]. Dtsch Med Wochens-chr 2009; 134(12): 565-570.
26. Pfutzner A, Asakura T, Sommavilla B, Lee W. Pfutzner A, Asakura T, Sommavilla B, Lee W. Insulin delivery with Flex-Pen: dose accuracy, patient preference and adherence. Expert Opin Drug Deliv 2008; 5(8): 915-925.
27. Sommavilla B, JØgensen C, Jensen KH. Safety, simplicity and convenience of a modified prefilled insulin pen. Expert Opin Pharmacother 2008; 9(13): 2223-2232.